Psychiatry and Clinical Neurosciences
April 18, 2023
Lucy Chester, Lucia Valmaggia, Matthew J. Kempton et al.
Evidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However, there have been limited prospective studies and the direction of this association remains controversial. The primary aim of the present study was to examine the association between cannabis use and the incidence of psychotic disorders in people at clinical high risk of...
Neuropsychopharmacology
November 16, 2022
Amir Englund, D. Oliver, Edward Chesney et al.
As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful effects of cannabis use. This study aimed to determine if increasing the CBD content of cannabis can reduce its harmful effects. Forty-six healthy, infrequent cannabis users participated in a double-blind, within-subject, randomised trial of cannabis preparations...
2020
D. Oliver, Gemma Modinos, P. McGuire
Abstract Although clinical intervention at the clinical high risk stage has the potential to prevent the onset of psychosis, there are still no licensed pharmacological treatments for this purpose. The development of preventative treatments is informed by models of psychosis onset, especially those that reflect the time course and symptomatology of the disorder. This chapter describes four...
Schizophrenia Bulletin Open
2020
Musa Sami, Robert A. McCutcheon, Ulrich Ettinger et al.
Both chronic cannabis use and psychotic disorders are associated with abnormalities in visual attentional processing. Using functional magnetic resonance imaging (fMRI), we sought to determine whether there would be a difference in functional connectivity in patients and controls with and without a history of cannabis use in the visual and dorsal attention networks. Resting-state fMRI data were...
European Neuropsychopharmacology
July 1, 2018
Marco Colizzi, P. McGuire, Vincent Giampietro et al.
Cannabis use has been associated with psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (-)-trans-Δ9-tetrahydrocannabinol (∆9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in...
The Lancet Psychiatry
October 1, 2016
Tabea Schoeler, Natalia Petros, Marta Di Forti et al.
BACKGROUND Although cannabis use after a first episode of psychosis has been associated with relapse, little is known about the determinants of this most preventable risk factor for relapse of psychosis. Here we aimed to study whether the effects on outcome vary depending on the type of cannabis consumed and usage pattern. METHODS In this observational study, we prospectively recruited and...
BMJ Open
2016
R. Patel, R. Wilson, R. Jackson et al.
Objective To investigate whether cannabis use is associated with increased risk of relapse, as indexed by number of hospital admissions, and whether antipsychotic treatment failure, as indexed by number of unique antipsychotics prescribed, may mediate this effect in a large data set of patients with first episode psychosis (FEP). Design Observational study with exploratory mediation analysis....